As part of our Bald Girls community, you know firsthand the impacts of alopecia areata. That’s also what the FDA wants to learn. They held an AA patient-focused meeting in September 2017 attended by Bald Girls Do Lunch CEO, Thea Chassin.
Our submissions page to Talk to the FDA via the Bald Girls Do Lunch impact statement is now closed.
You may enter your comments through 11:59 pm eastern, November 13, 2017 directly to the FDA here.
Thinking something? Say something! Thea Chassin reviews the meeting.
FDA’s taking patient and family comments until November 13, 2017.
Alopecia Areata Slated for FDA Hearings http://bgdl.org/1LeuyGa
Bald Girls Do Lunch Announces FDA Hearings on #AlopeciaAreata #alopecia
The FDA has been holding public meetings on 20 different disease areas, one disease per area over the last year or so to continue through 2017. Alopecia Areata is on a preliminary list to be chosen as a disease in the FDA’s process for patient-focused input for the 2016-2017 disease-specific meetings. The FDA is currently inviting commentary on this preliminary list.
- Bald Girls Do Lunch is giving our network a quick way to give feedback to the FDA.
- The FDA staff wants your views to better understand patients’ opinions about which diseases patients consider to be a high priority.
- Our easy form and quick guidelines will focus your feedback. Act now!
Submit your feedback by December 5th, 2014.